Take Limited Posts Q1 FY27 Turnaround with Revenue of 30.37 Cr; Enters Longevity Sector
CHENNAI, August 11, 2026 - TAKE Limited, a global technology-driven healthcare company, announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY 2026-27). The Company demonstrated significant operational momentum, reporting Consolidated Revenue from Operations of ₹3,037.33 Lakhs (₹30.37 Crore) and a Consolidated Net Profit of ₹106.26 Lakhs (₹1.06 Crore), successfully reversing a net loss of (91.00) Lakhs recorded in the corresponding prior-year period.The Board of Directors considered and approved these unaudited financial results, along with the Limited Review Reports thereon, at its meeting held on August 11, 2026.
Key Financial Performance Highlights
The Company showed marked expansion across both consolidated and standalone operations in Q1 FY26-27. Consolidated Revenue from Operations expanded dramatically to ₹3,037.33 Lakhs compared to Nil revenue recorded in the previous year's quarter. Total Income reached ₹3,170.11 Lakhs (₹31.70 Crore).A key operational efficiency gain was seen in finance costs, which plummeted by 99.62% Year-on-Year (YoY) to just ₹0.07 Lakhs, down from ₹17.50 Lakhs in the previous quarter.
Standalone performance also showed a strong turnaround for the company. Standalone Revenue from Operations surged to ₹1,196.90 Lakhs (up from ₹0.65 Lakhs in Q1 FY26), and Net Profit turned around significantly to ₹96.83 Lakhs (versus a net loss of ₹216.45 Lakhs in the prior quarter).
Strategic Focus on Longevity and Preventive Healthcare
Building upon its strengthened financial base, TAKE Limited has announced a strategic entry into the rapidly accelerating Longevity, Biohacking, and Preventive Healthcare market. The company's strategy involves integrating science-backed nutraceuticals and biohacking consumer products with technology-enabled predictive digital tools designed to track and optimize metabolic health, sleep, cognition, and biological aging.Parmeshvar Dhangare, Director of TAKE Limited, stated that the Q1 FY27 results reflect the successful stabilization and revitalization of the company’s operational framework. He noted that the entry into the Longevity and Anti-Ageing sector positions TAKE Limited at the intersection of life sciences, technology, and consumer wellness.
The market opportunity remains substantial; global longevity is projected to grow from USD 27.61 Billion in 2025 to USD 67.03 Billion by 2035 (at a 9.41% CAGR). In the Indian context, the anti-aging supplements segment is expected to expand from USD 168.6 Million in 2025 to USD 341.4 Million by 2033 (9.5% CAGR).
Financial Summary Tables
The following tables provide a detailed comparison of the Company’s performance across Q1 FY26-27, compared to previous periods.Consolidated Financial Results (₹ in Lakhs)
| Particular | 3 months ended 30.06.2026 (Unaudited) | Preceding 3 months (Audited) | Corresponding 3 months in FY25 (Unaudited) | Previous Year (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 3,037.33 | 5,418.53 | 0.00 | 5,418.53 |
| Other Income | 132.78 | 518.49 | 4.10 | 668.73 |
| Total Income | 3,170.11 | 5,937.02 | 4.10 | 6,087.26 |
| Total Expenses | 3,063.85 | 5,501.03 | 62.60 | 5,645.66 |
| Profit/(Loss) before Tax | 106.26 | 435.99 | -58.50 | 441.60 |
| Net Profit/(Loss) | 106.26 | 435.99 | -91.00 | 1,084.90 |
Standalone Financial Results (₹ in Lakhs)
| Particular | 3 months ended 30.06.2026 (Unaudited) | Preceding 3 months (Audited) | Corresponding 3 months in FY25 (Unaudited) | Previous Year (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 1,196.90 | 0.00 | 0.65 | 0.00 |
| Net Profit/(Loss) | 96.83 | 439.18 | -216.45 | 271.91 |
TAKE Stock Price Movement
On Tuesday, Take Solutions Limited shares edged higher, settling at ₹23.25 after closing with a 1.13% gain. The stock traded within an intraday range of ₹22.22 and ₹23.45, recording a total volume of 1.33 million shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: